• GLP‑1 drugs treat obesity, heart disease, diabetes but may raise pancreatitis risk. • UK MHRA warns of acute pancreatitis after 19 deaths linked to GLP‑1 drugs. • Brazil reports six deaths, echoing UK concerns about severe pancreatic inflammation. • Pancreatitis risk already listed in drug leaflets, yet recent reports have surged. • Causality remains unclear; increased use likely leads to more adverse event reports. • Experts call for vigilant monitoring and rigorous studies to clarify rare side‑effects.
Article Summaries:
- The United Kingdom and Brazil have issued stronger warnings about a possible link between GLP‑1 weight‑loss drugs and pancreatic inflammation. The UK Medicines and Healthcare products Regulatory Agency (MHRA) noted a rise in pancreatitis reports, including 19 deaths in the UK and six in Brazil, but experts say the overall risk remains very small given the millions of people on these medications. Evidence from clinical trials is mixed; a 2025 meta‑analysis suggested a slight increase in pancreatitis risk, while other studies found no association. Regulators and clinicians call for vigilant monitoring and further research to clarify the rare adverse‑event profile.
Sources: